Otsuka Pharm Drug Patent Portfolio

Otsuka Pharm's Family Patents

Title	Lead Sponsor	Collaborators	Status	Phases

Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia	Otsuka Pharmaceutical Europe Ltd	H. Lundbeck A/S	UNKNOWN (Apr, 2019)
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.	Otsuka Pharmaceutical Development & Commercialization, Inc.	NA	TERMINATED (Jan, 2016)	PHASE3
Aripiprazole for the Augmentation of Antidepressant Therapy	Taiwan Otsuka Pharm. Co., Ltd	NA	COMPLETED (May, 2014)	PHASE4
Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder	Otsuka Pharmaceutical Development & Commercialization, Inc.	Otsuka America Pharmaceutical	COMPLETED (Feb, 2013)	PHASE3
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Otsuka America Pharmaceutical	COMPLETED (Aug, 2008)	PHASE4
Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders	Otsuka Pharmaceutical Development & Commercialization, Inc.	NA	COMPLETED (Sep, 2007)	PHASE2, PHASE3

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List